Cargando…

A Pre-Clinical Study of Sub-Anesthetic Ketamine as Remedy in 5-Fluorouracil-Induced Cachexia Model

Around 0.5–1% of the world population is suffering from cachexia. In particular, cancer patients under cancer radio-chemotherapy have a high prevalence of cachexia, especially during the end stages of therapeutic treatment. Clinically, chemotherapeutic 5-fluorouracil (5-Fu) treatment often leads to...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, James, Lin, Zen-Cheng, Weng, Brian Bor-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866993/
https://www.ncbi.nlm.nih.gov/pubmed/36675959
http://dx.doi.org/10.3390/life13010008
_version_ 1784876231491059712
author Wang, James
Lin, Zen-Cheng
Weng, Brian Bor-Chun
author_facet Wang, James
Lin, Zen-Cheng
Weng, Brian Bor-Chun
author_sort Wang, James
collection PubMed
description Around 0.5–1% of the world population is suffering from cachexia. In particular, cancer patients under cancer radio-chemotherapy have a high prevalence of cachexia, especially during the end stages of therapeutic treatment. Clinically, chemotherapeutic 5-fluorouracil (5-Fu) treatment often leads to the development of adverse effects, such as leukopenia, immune dysfunction, anorexia, muscle wasting, etc., and 5-Fu also tends to exacerbate the occurrence of cancer cachexia. Currently, there are very limited drug choices when seeking to revive cachexia patient’s health quality while enduring a full therapeutic regimen as part of advanced cancer therapy. The present study employed chemotherapeutic drug 5-Fu-induced cachexia-like conditions in Balb/c mice. After 8 days of 5-Fu treatment, mice had begun to show cachexia-like symptoms such as weight loss and reduced food intake. After one day of washing out, the cachexia animals received a single dose of either saline solution as a mock dose or a low dose (15 mg/kg BW) or high dose (30 mg/kg BW) of ketamine at day 10. For the following 7 days, food intake, body weight, and mortality were monitored. Data were analyzed with the LOCF (last observation carried forward) method. Improved survival rates were obtained in ketamine groups. Ketamine administration at the high dose of 30 mg/kg BW demonstrated effectively diminished weight loss due to cachexia, and also successfully improved overall survival. The current study demonstrates that a sub-anesthetic level of ketamine administration supports overall beneficial outcomes in 5-Fu-induced cachexia and outlook as a potential clinical remedy.
format Online
Article
Text
id pubmed-9866993
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98669932023-01-22 A Pre-Clinical Study of Sub-Anesthetic Ketamine as Remedy in 5-Fluorouracil-Induced Cachexia Model Wang, James Lin, Zen-Cheng Weng, Brian Bor-Chun Life (Basel) Communication Around 0.5–1% of the world population is suffering from cachexia. In particular, cancer patients under cancer radio-chemotherapy have a high prevalence of cachexia, especially during the end stages of therapeutic treatment. Clinically, chemotherapeutic 5-fluorouracil (5-Fu) treatment often leads to the development of adverse effects, such as leukopenia, immune dysfunction, anorexia, muscle wasting, etc., and 5-Fu also tends to exacerbate the occurrence of cancer cachexia. Currently, there are very limited drug choices when seeking to revive cachexia patient’s health quality while enduring a full therapeutic regimen as part of advanced cancer therapy. The present study employed chemotherapeutic drug 5-Fu-induced cachexia-like conditions in Balb/c mice. After 8 days of 5-Fu treatment, mice had begun to show cachexia-like symptoms such as weight loss and reduced food intake. After one day of washing out, the cachexia animals received a single dose of either saline solution as a mock dose or a low dose (15 mg/kg BW) or high dose (30 mg/kg BW) of ketamine at day 10. For the following 7 days, food intake, body weight, and mortality were monitored. Data were analyzed with the LOCF (last observation carried forward) method. Improved survival rates were obtained in ketamine groups. Ketamine administration at the high dose of 30 mg/kg BW demonstrated effectively diminished weight loss due to cachexia, and also successfully improved overall survival. The current study demonstrates that a sub-anesthetic level of ketamine administration supports overall beneficial outcomes in 5-Fu-induced cachexia and outlook as a potential clinical remedy. MDPI 2022-12-20 /pmc/articles/PMC9866993/ /pubmed/36675959 http://dx.doi.org/10.3390/life13010008 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Wang, James
Lin, Zen-Cheng
Weng, Brian Bor-Chun
A Pre-Clinical Study of Sub-Anesthetic Ketamine as Remedy in 5-Fluorouracil-Induced Cachexia Model
title A Pre-Clinical Study of Sub-Anesthetic Ketamine as Remedy in 5-Fluorouracil-Induced Cachexia Model
title_full A Pre-Clinical Study of Sub-Anesthetic Ketamine as Remedy in 5-Fluorouracil-Induced Cachexia Model
title_fullStr A Pre-Clinical Study of Sub-Anesthetic Ketamine as Remedy in 5-Fluorouracil-Induced Cachexia Model
title_full_unstemmed A Pre-Clinical Study of Sub-Anesthetic Ketamine as Remedy in 5-Fluorouracil-Induced Cachexia Model
title_short A Pre-Clinical Study of Sub-Anesthetic Ketamine as Remedy in 5-Fluorouracil-Induced Cachexia Model
title_sort pre-clinical study of sub-anesthetic ketamine as remedy in 5-fluorouracil-induced cachexia model
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866993/
https://www.ncbi.nlm.nih.gov/pubmed/36675959
http://dx.doi.org/10.3390/life13010008
work_keys_str_mv AT wangjames apreclinicalstudyofsubanestheticketamineasremedyin5fluorouracilinducedcachexiamodel
AT linzencheng apreclinicalstudyofsubanestheticketamineasremedyin5fluorouracilinducedcachexiamodel
AT wengbrianborchun apreclinicalstudyofsubanestheticketamineasremedyin5fluorouracilinducedcachexiamodel
AT wangjames preclinicalstudyofsubanestheticketamineasremedyin5fluorouracilinducedcachexiamodel
AT linzencheng preclinicalstudyofsubanestheticketamineasremedyin5fluorouracilinducedcachexiamodel
AT wengbrianborchun preclinicalstudyofsubanestheticketamineasremedyin5fluorouracilinducedcachexiamodel